Sunshine Biopharma Inc
NASDAQ:SBFM
Sunshine Biopharma Inc
Research & Development
Sunshine Biopharma Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Sunshine Biopharma Inc
NASDAQ:SBFM
|
Research & Development
-$680.1k
|
CAGR 3-Years
8%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-49%
|
|
|
B
|
Bright Minds Biosciences Inc
CNSX:DRUG
|
Research & Development
-CA$11.1m
|
CAGR 3-Years
3%
|
CAGR 5-Years
-125%
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Research & Development
-$29.7m
|
CAGR 3-Years
14%
|
CAGR 5-Years
10%
|
CAGR 10-Years
-7%
|
|
|
X
|
Xenon Pharmaceuticals Inc
NASDAQ:XENE
|
Research & Development
-$272.7m
|
CAGR 3-Years
-43%
|
CAGR 5-Years
-42%
|
CAGR 10-Years
-34%
|
|
|
Eupraxia Pharmaceuticals Inc
TSX:EPRX
|
Research & Development
-CA$14.9m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-38%
|
CAGR 10-Years
N/A
|
|
|
e
|
enGene Holdings Inc
NASDAQ:ENGN
|
Research & Development
-$94.5m
|
CAGR 3-Years
-83%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Sunshine Biopharma Inc
Glance View
Sunshine Biopharma, Inc. engages in the research, development, and commercialization of oncology and antiviral drugs. The company is headquartered in Pointe-Claire, Quebec and currently employs 3 full-time employees. The company went IPO on 2008-08-15. In addition, the Company is engaged in the development and commercialization of science-based nutritional supplements. The Company’s drug development operations include SBFM-PL4 Anti-Coronavirus Treatment and Adva-27a Anticancer Drug. The firm is engaged in the development of its Anti-Coronavirus compound, SBFM-PL4. The company is advancing the development of two compounds in parallel with its SBFM-PL4. The Company’s drug development activities have focused on the development of a small molecule, Adva-27a for the treatment of aggressive forms of cancer. A Topoisomerase II inhibitor, Adva-27a has been shown to be effective at destroying Multidrug Resistant Cancer cells, including Pancreatic Cancer cells, Breast Cancer cells, Small-Cell Lung Cancer cells and Uterine Sarcoma cells.
See Also
What is Sunshine Biopharma Inc's Research & Development?
Research & Development
-680.1k
USD
Based on the financial report for Sep 30, 2025, Sunshine Biopharma Inc's Research & Development amounts to -680.1k USD.
What is Sunshine Biopharma Inc's Research & Development growth rate?
Research & Development CAGR 10Y
-49%
Over the last year, the Research & Development growth was 58%. The average annual Research & Development growth rates for Sunshine Biopharma Inc have been 8% over the past three years , and -49% over the past ten years .
